3Ohta K, Nishiki Kosaka S, Nakao Y,et al. Efficacy and safety of intravenous itraconazole as empirical antifungal therapy for persistent fever in neutropenic patients with hematological malignancies in Japan. Int J Hematol, 2009, 89 (5) :649 -655.
4Bohme A, Ruhnke M, Buchheidt D,et al. Treatment of invasive fungal infections in cancer patients - -recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol,2009,85(2) :97 - 110.
5Mondal RK, Singhi SC, Charkrabarti A ,et al. Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit a preliminary study. Pediatr Crit Care Med, 2004,5 (6) :561 - 565.
6Boogaerts M, Winston D J, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad - spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med, 2001,135(6) :412 -422.
8Weiberger M. Sacks T, Sulkes J, et al, Increasing fungal isolation from clinical specimens: experience in a university hospital over a decade[J]. J Hosp Infect, 1997,35(1):185-188.
